A Study Comparing the Efficacy of TA103 and the Placebo Control in the Treatment of Interdigital Tinea Pedis.

NCT04883593 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Tinea Pedis

Interventions

DRUG: TA103
DRUG: Placebo Control

Sponsor

Sun Pharmaceutical Industries, Inc.